Sagimet Biosciences (SGMT) Income towards Parent Company (2022 - 2026)

Sagimet Biosciences' Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$10.6 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 41.41% year-over-year to -$10.6 million; the TTM figure through Mar 2026 stood at -$43.5 million (up 23.82% YoY), while the FY2025 annual figure was -$51.0 million, down 12.01% from the prior year.
• Income towards Parent Company was -$10.6 million for Q1 2026 at Sagimet Biosciences, down from -$9.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$6.4 million in Q3 2023 to a low of -$18.2 million in Q1 2025.
• Historically, Income towards Parent Company has averaged -$9.8 million across 5 years, with a median of -$8.1 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Income towards Parent Company plunged 174.19% in 2025, then soared 41.41% in 2026.
• A 5-year view of Income towards Parent Company shows it stood at -$7.2 million in 2022, then dropped by 13.3% to -$8.2 million in 2023, then sank by 98.74% to -$16.2 million in 2024, then soared by 40.94% to -$9.6 million in 2025, then dropped by 11.31% to -$10.6 million in 2026.
• The last three Income towards Parent Company figures came in at -$10.6 million (Q1 2026), -$9.6 million (Q4 2025), and -$12.9 million (Q3 2025), per Business Quant data.